# SUNMO (NCT05171647)

> A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05171647
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Hodgkin Lymphoma
- Interventions: Mosunetuzumab; Polatuzumab vedotin; Tocilizumab; Rituximab; Gemcitabine; Oxaliplatin
- Enrollment: 208
- Primary outcome: Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
- Primary outcome: Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

## Commentary we found

- YouTube: 37
- Podcasts: 19
- X threads: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sunmo-nct05171647

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05171647", "email": "<work email>"}; the inbox owner confirms by the emailed link.